tbuckley/cabot-search huggingface dataset:
OA09.05 Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
Authors: M. Alexander, Y. Cheng, S.-H. Lee, A. Passaro, A.I. Spira, B.C. Cho, S.M. Lim, Y. Ohe, A. Nagrial, J.L. Tan, V. Wainsztein, E. Ramos, M. del Rosario Garcia Campelo, H. Akamatsu, D. Nguyen, A.B. Cortot, A. Zer, D. Erdem, R.E. Sanborn, T.-O. Emde, A.R. Minchom, B. Zurawski, M.L. Ferreira, J.C.-H. Yang, M.E. Marmarelis, J. Schuchard, J. Alves, D. Ghosh, R.B. Verheijen, M. Gamil, J.M. Bauml, M. Baig, N.B. Leighl
Journal: Journal of Thoracic Oncology (2024)
OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
Authors: H. Horinouchi, B.J. Solomon, Y.-L. Wu, F. Barlesi, M. Nishio, J.S. Ahn, D.H. Lee, J.-S. Lee, W. Zhong, M. Hochmair, I. Bondarenko, D. Planchard, A. Rittmeyer, B. Ding, T. Ruf, L. Adler, A. Scalori, R. Dziadziuszko
Journal: Journal of Thoracic Oncology (2024)
MA11.05 Nivolumab + Ipilimumab vs Chemotherapy in Patients with Stage IV/recurrent NSCLC and PD-L1 ≥ in China: Checkmate 227 CHESS
Authors: Y.-L. Wu, X. Wu, K. Ying, G. Chen, Z. Wang, W. Lin, S. Lu, H. Zhong, Y. Cheng, J. Cui, M. Wang, K. Wang, B. Zhu, X. Yu, Y. Chen, C. Liu, Y. Yao, H. Sun, S. Wang, M. Tschaika, M. Pe Benito, A. Lee, Y. Yuan, L. Wu
Journal: Journal of Thoracic Oncology (2024)
OA03.03 The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing
Authors: M. Smeltzer, C. Connolly, S. Lantuejoul, R. Soo, A. Kerpel-Fronius, A. Mohan, G. Woodard, U. Basu Roy, M. Chau, K. Brunson, R. Santos, M. Wynes, J.C. King, A. Young, Y. Yatabe, K. Kelly
Journal: Journal of Thoracic Oncology (2024)
MA10.07 Understanding Symptom Burden in Young Adults with Lung Cancer Based on an Analysis from the E2C2 Pragmatic Clinical Trial
Authors: K. Smith, K. Leventakos, V. Grzegorczyk, J. Griffin, B. Liu, S. Mina, D. Pachman, K. Ruddy, A. Cheville
Journal: Journal of Thoracic Oncology (2024)
MA12.11 Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI
Authors: W. Li, G. Che, J. Zhao, Y. Zhao, J. Duan, C. Zhou, X. Zhao, L. Wu, Y. Zhang, C. Zhou, C. Zhou, F. Zhou
Journal: Journal of Thoracic Oncology (2024)
OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRAS G12C-Mutant Advanced NSCLC
Authors: Y. Fujiwara, N. Reddy Ammakkanavar, A. Hollebecque, Y.R. Murciano-Goroff, D.H. Lee, T.F. Burns, P. Cassier, J.-Y. Han, A. Italiano, T. Koyama, B.Y. Shim, R.S. Heist, J.K. Sabari, A.I. Spira, J. Bodor, Q. Chu, G. Durm, N. Singhal, M.J. Chisamore, A. Fink, A. Chen, M.D. Willard, G.R. Oxnard, K.H. Dragnev
Journal: Journal of Thoracic Oncology (2024)
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
Authors: J. Sands, B.C. Cho, M.-J. Ahn, M. Reck, J. Bustamante-Alvarez, H.-D. Hummel, H. Akamatsu, M.L. Johnson, E. Felip, S. Handzhiev, I. Korantzis, H. Izumi, A.-M. Dingemans, F. Blackhall, T.K. Owonikoko, J. Wolf, S.S. Ramalingam, H. Borghaei, S. Huang, T. Jiang, E.S. Anderson, P. Martinez, A. Hamidi, S. Mukherjee, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2024)
OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
Authors: Q. Zhou, X. Meng, L. Sun, D. Huang, N. Yang, Y. Yu, M. Zhao, W. Zhuang, Y. Hu, Y. Pan, M. Sun, J. Shan, R. Guo, Q. Chu, C. Xu, J. Lin, J. Huang, M. Huang, S. Zhang, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
OA05.03 Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial
Authors: S. Yang, B. Chen, J. Yu, X. Liu, T. Jiang, F. Wu, A. Li, G. Gao, X. Chen, S. Ren
Journal: Journal of Thoracic Oncology (2024)
OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer
Authors: C. Wang, X. Zhao, L. Zhang, D. Yue, Z. Zhang, M. Wang, Z. Tian, S. Wang, C. Pang, B. Zhang, Q. Zhang, W. Wei, Y. Zhang, X. Wang, Y. Li, H. Lv, Y. Xia, B. Li, Z.M. Wang, W. Li
Journal: Journal of Thoracic Oncology (2024)
MA06.08 Kinetics and Management of Adverse Events Associated with Lorlatinib after 5 Years of Follow-Up in the CROWN Study
Authors: T. Bauer, B.J. Solomon, J. Mazieres, D.-W. Kim, D. Cortinovis, T. Inoue, R. Sharma, H. Thurm, A. Polli, G. Liu
Journal: Journal of Thoracic Oncology (2024)
OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01
Authors: C.M. Rudin, M.-J. Ahn, M. Johnson, C.L. Hann, N. Girard, M. Nishio, Y. Cheng, H. Hayashi, Y. Jung Kim, A. Navarro, Y. Chen, T. Sakai, M. Qian, J. Godard, M. Tang, J. Singh, L. Paz-Ares
Journal: Journal of Thoracic Oncology (2024)
OA08.06 Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1-containing Regimen: EVOKE-01
Authors: M.C. Garassino, O. Juan-Vidal, E. Felip, N. Girard, M. Cobo Dols, D.E. Haggstrom, N. Reinmuth, M. Tiseo, M.J. Hochmair, Y. Summers, L.E.L. Hendriks, D.B. Daniel, T. Kato, P. Cheema, S. Mekan, R. Patel, E. Zhang, L.G. Paz-Ares
Journal: Journal of Thoracic Oncology (2024)
PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01
Authors: M.C. Garassino, J. Sands, L. Paz-Ares, A. Lisberg, M. Johnson, M. Pérol, D. Carroll, H. Sade, A. Kapil, V. Haddad, D. Uema, M.-J. Ahn
Journal: Journal of Thoracic Oncology (2024)
PL04.13 Aumolertinib Maintenance after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer: Interim Results of the Phase III Study (POLESTAR)
Authors: J. Yu, X. Meng, H. Ge, Q. Liu, F. Ning, Y. Cheng, J. Wang, X. Zhang, G. Wu, J. Chen, Y. Xu, X. Zhao, K. Lu, O. Jiang, D. Lv, C. Xie, X. Li, Y. Yao, X. Dong, B. Liu, J. Fang, K. Yang, B. Zhu, Q. Lin, J. Shi, S. Ye, A. Shi, S. Cang, J. Li, B. Xu, H. Li, Z. Zhang, J. Yin, G. Wang, C. Liu
Journal: Journal of Thoracic Oncology (2024)
OA18.06 Characteristics and Outcomes of Patients with SMARCA4-Deficient Undifferentiated Thoracic Tumors
Authors: A. Cooper, B. Ricciuti, A. Gagne, L. Sholl, A. Di Federico, M. Awad, M. Aldea, M.R. Ghigna, M. Grecea, J. Chaft, M. Kris, G. Riely, C. Rudin, I. Dagogo-Jack, M. Mino-Kenudson, L. Hong, N. Kalhor, N. Vokes, N. Rekhtman, A. Schoenfeld
Journal: Journal of Thoracic Oncology (2024)
OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer
Authors: N.J. Choudhury, H. Beltran, M.L. Johnson, E.L. Schenk, R.E. Sanborn, J.R. Thompson, H. Mamdani, A. Dowlati, R.R. Aggarwal, A.W. Gramza, P. Jain
Journal: Journal of Thoracic Oncology (2024)
MA08.05 Lung Cancer in Young Adults is Associated with Advanced Disease at Diagnosis and Increased Frequency of Targetable Mutations
Authors: F. Oezkan, M. Webendoerfer, J. Winantea, M. Wiesweg, M. Metzenmacher, D. Theegarten, K. Darwiche, S. Bölükbas, F. Doerr, C. Taube, M. Stuschke, M. Opitz, M. Schuler, W.E.E. Eberhardt
Journal: Journal of Thoracic Oncology (2024)
OA07.03 The Effect of Personalized Music Therapy on Perioperative Pain and Anxiety in NSCLC Patients
Authors: Y. Yuan, Y. Ku, W. Huang, M. Zheng, Y. Zhou, Y. Lin, R. Te, H. Zhou, J. Zhao, W. Lin, Q. Chen, B. Rao, S. Feng, J. Zhong, L. Kang, H. Long
Journal: Journal of Thoracic Oncology (2024)
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816
Authors: P.M. Forde, S. Peters, J. Donington, S. Meadows-Shropshire, P. Tran, S. Lucherini, C. Coronado Erdmann, H. Sun, T. Cascone
Journal: Journal of Thoracic Oncology (2024)
PL04.04 Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
Authors: G. Ruiter, H.-Y. Tu, M.-J. Ahn, K. Yoh, J. Zugazagoitia, E. Smit, Y.-L. Wu, D. Planchard, B.-C. Cho, B. Wehler, Y. Zhao, U. von Wangenheim, M. Rohrbacher, B. Sadrolhefazi, G. Lin, Y. Yu, E. Nadal, J. Heymach
Journal: Journal of Thoracic Oncology (2024)
MA08.09 Predictive CT Features of Visceral Pleural Invasion in Lung Cancer with Ground Glass Opacity
Authors: N. Hayashi, K. Suzawa, K. Okada, T. Ryuko, Y. Tomioka, S. Tanaka, K. Miyoshi, K. Shien, M. Okazaki, S. Sugimoto, S. Toyooka
Journal: Journal of Thoracic Oncology (2024)
OA02.03 Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study
Authors: S. Gadgeel, B.C. Cho, S. Lu, E. Felip, H. Hayashi, A.I. Spira, B. Besse, M. Thomas, S. Owen, Y.J. Kim, S.-H. Lee, J. Mourão Dias, Y.-G. Lee, Y. Zhao, Y. Fang, N. Girard, Z. Liu, P. Sun, S.C. Sousa Oliveira, H. Shen, L. Paz-Ares, S. Matsumoto, H. Tanaka, A.R. Ahmad, T. Andabekov, P. Sunpaweravong, O. Ozyilkan, J.C.-H. Yang, M. Gottfried, O. Hernandez, M. Kimmich, D. Cortinovis, D.L. Kaen, L.V. García Montes, S. Popat, T. Newsom-Davis, J. Xie, T. Sun, E. Fennema, M. Daksh, M. Ennis, S. Sethi, J.M. Bauml, D. Nguyen
Journal: Journal of Thoracic Oncology (2024)
MA04.11 Women Enrolled in Lung Screening as a Result of Direct Outreach Are More Likely to be Cancer Survivors
Authors: S. Faltaous, S.A. Deppen, S. Joyner, A. Paulson, S. Valenti, E.A. Kazerooni, R.A. Smith, C. Thomson, K.L. Sandler
Journal: Journal of Thoracic Oncology (2024)
OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA
Authors: S.-H. Lee, B.C. Cho, H. Hayashi, E. Felip, A.I. Spira, N. Girard, Y.J. Kim, Y. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E. Korbenfeld, J. Mourão Dias, K.H. Lee, H. Xiong, S.H. How, Y. Cheng, G.-C. Chang, J.C.-H. Yang, B. Besse, M. Thomas, J.C. Curtin, J. Zhang, J. Xie, T. Sun, M. Martinez, S. Sethi, R.E. Knoblauch, E. Fennema, M. Daksh, M. Ennis, J.M. Bauml, S. Lu
Journal: Journal of Thoracic Oncology (2024)
OA06.03 SAFFRON-301: Tislelizumab Plus Sitravatinib in Advanced/Metastatic NSCLC Progressing on/after Chemotherapy and Anti-PD-(L)1
Authors: Q. Zhou, B. Gao, J. Hu, J. Zhao, M. Wang, K. He, W. Zhang, C. Liu, J. Fang, X. Li, Z. Wang, M. Matos, V. Kwatra, X. Li, Y. Chen, J. Zhang, J. Wang, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
MA03.08 Differential Impact of Sublobar Resection on Visceral Pleural Invasion Classification
Authors: D. Lee, S. Park, S.J. Lee, T.Y. Yoon, J.H. Park, B.S. Na, K.J. Na, I.K. Park, C.H. Kang, Y.T. Kim
Journal: Journal of Thoracic Oncology (2024)
OA08.03 Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Authors: J. Sands, A. Lisberg, I. Okamoto, L. Paz-Ares, R. Cornelissen, N. Girard, E. Pons-Tostivint, D. Vicente, S. Sugawara, M. Cobo Dols, M. Pérol, C. Mascaux, E. Poddubskaya, S. Kitazono, H. Hayashi, M.H. Hong, E. Felip, R. Hall, O. Juan-Vidal, D. Brungs, S. Lu, M. Garassino, E. Alexandris, Y. Zhang, P. Howarth, D. Uema, M.-J. Ahn
Journal: Journal of Thoracic Oncology (2024)
OA08.05 Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC: Results from Phase 3 CARMEN-LC03 Trial
Authors: B. Besse, G. Lo Russo, H. Lena, E. Nadal, S. Cousin, D. Kowalski, M. Johnson, S. Novello, H. Bischoff, N. Girard, J.-L. Pujol, L. Paz-Ares, S. Yoruk, A. Tellier, B.C. Cho
Journal: Journal of Thoracic Oncology (2024)
OA07.04 Optimising Care of Older Patients with Lung Cancer - An Innovative Nurse-led Model of Care
Authors: S. Vinod, N. Knox, K. Knight, V. Bray, A. Khoo, E. Tcharkhedian, J. Campisi, P. Dufton, G. McErlean, M. Agar, L. Hickman
Journal: Journal of Thoracic Oncology (2024)
OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)
Authors: J. Wang, J. Duan, L. Wu, Q. Wang, L. Xing, Y. Sun, P. Lu, F. Ning, H. Yang, H. Su, W. Yao, P. Pan, H. Yang, J. Zhang, J. Huang, J. Chen, Y. Cheng, Y. Li, X. Dong, H. Shi, H. Yang, A. Zeng, Z. He, X. Pei, P. Pang, H. Sun, Y. Zhou, M. Zhang, Y. Dong
Journal: Journal of Thoracic Oncology (2024)
MA05.04 Targeting TROP-2 In Diffuse Pleural Mesothelioma
Authors: M.D. Offin, S. Tischfield, P. Manoj, P. Agrawal, S. Tendler, E.C. Pratt, W. Travis, A. Rimner, C.B. Simone, E. de Stanchina, J. Qiu, V. Markov, M. Donoghue, J.S. Lewis, M.G. Kris, J.L. Sauter, P.S. Adusumilli, C.M. Rudin, A. Quintanal Villalonga, M.G. Zauderer
Journal: Journal of Thoracic Oncology (2024)
OA05.04 Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study
Authors: L.J. Brown, J. Ahn, B. Gao, H. Gee, A. Nagrial, I.E.D.P. Da Silva, E. Hau
Journal: Journal of Thoracic Oncology (2024)
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
Authors: J. Yang, A. Li, W.N. Feng, J. Li, H.H. Yan, B.F. Xu, J. Zhao, Y. Jia, K.J. Tang, Y.S. Li, C.Z. Zhou, Y. Fan, C.R. Xu, Y.L. Sun, H.J. Chen
Journal: Journal of Thoracic Oncology (2024)
OA04.04 Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
Authors: A. Dowlati, A.C. Chiang, A. Cervantes, S. Babu, E. Hamilton, S.F. Wong, A. Tazbirkova, I.G. Sullivan, C. van Marcke, A. Italiano, J. Patel, S. Mekan, T. Wu, S.N. Waqar
Journal: Journal of Thoracic Oncology (2024)
MA07.08 Proteogenomic Analysis of CSF Reveals Distinct Molecular Patterns of Leptomeningeal Metastases in EGFR-Mutated NSCLC
Authors: M.-M. Zheng, S.-H. Lin, Y.-S. Li, K. Yin, P. Li, X.-C. Zhang, S.-X. Gao, Q. Zhou, H.-Y. Tu, J.-J. Yang, H.-J. Chen, Y. Pan, B.-C. Wang, Z. Wang, C.-R. Xu, F.-M. Xiao, W.-Z. Zhong, H.-H. Yan, L.-B. Tang, L. Wu, L. Zeng, S.-Y.M. Liu, C.C. Wong, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Authors: X. Le, Y. Yu, Y. Zhao, D. Planchard, Y. Cheng, X. Li, S. Gadgeel, J. Zhang, A. Spira, H. Hayashi, J. Riess, S. Kitazono, N. Leighl, B. Gao, O. Juan-Vidal, A.J. de Langen, J. Mazieres, M. Pérol, Y. Jiang, T. Hu, J. Huang, N. Baio, L. Musib, M. Kowanetz, S. Wang, W. Leung, S. Yea, J. Hsu, J. Wang
Journal: Journal of Thoracic Oncology (2024)
OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Authors: E. Felip, T.S.K. Mok, S. Lu, F. Barlesi, R. Jotte, G. Lo Russo, M. Reck, W. Yao, L. Doucet, A. Azkárate Martínez, V. Gregorc, O. Juan-Vidal, J. Raskin, H. Linardou, R. Raina, H. Penton, A. Lee, S.I. Blum, B. Korytowsky, M. Duruisseaux
Journal: Journal of Thoracic Oncology (2024)
MA08.12 Semi-Sold Lung Nodule Growth Rates, Need for Treatment, and Cancer-Specific Verses All-Cause Mortality in a Large North American Population
Authors: G.A. Woodard, E. Kane, S. Prince, J. Blasberg, A. Dhanasopon, D. Boffa, V. Mase, S. Dacic, A. Bader, F. Detterbeck
Journal: Journal of Thoracic Oncology (2024)
PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC
Authors: T. Cascone, G. Florian, L. Bonanno, M. Lieberman, O. Bylicki, A. Insa, L. Livi, R. Corre, T. Egenod, A. Bieslka, A. Yohannes, R. Mager, Y. He, A. Dowson, L. McGrath, R. Kumar, I. Grenga, J. Spicer, P. Forde
Journal: Journal of Thoracic Oncology (2024)
OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial
Authors: J.V. Heymach, D. Harpole, T. Mitsudomi, J.M. Taube, S. Gao, L. Urban, J.H. Kang, F.J. Orlandi, J. Rodriguez-Cid, B. Massuti, L.L. Mateos, G. Pasello, Q. Chu, J. Kolb-Sielecki, M. Nakata, M. Aperghis, H. Mann, T.M. Fouad, G.J. Doherty, M. Reck
Journal: Journal of Thoracic Oncology (2024)
MA01.04 AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Authors: L. Martin, X. Wang, D. Kozono, J. Urbanic, S. Graziano, R. Osarogiagbon, R.J. Mehran, J. Wain, C. Bestvina, J. Gannon, S. Wolf, T. Stinchcombe, J.D. Patel
Journal: Journal of Thoracic Oncology (2024)
PL02.14 Triaging ILST Screening Participants at Program Entry: Comparative Performance of PanCan versus LungRADSv1.1 Protocol
Authors: A.M. McWilliams, M. Tammemagi, S. Atkar-Khattra, J. Mayo, R. Meyers, J. Yee, J. English, H. Marshall, L. Passmore, R. Bowman, I. Yang, F. Brims, J. Logan, K.P. Lim, L. Mo, S. Melsom, B. Saffar, Y. Kwok, R. Sheehan, M. Teh, S. Dormer, E. Stone, E. Hsu, X. Hu, B. Milner, D. Nguyen, C. Rofe, E. Silverstone, R. Manser, D. Pascoe, M. McCusker, D. Steinfort, L. Irving, A. Bonney, D. Lam, M.-Y. Lam, V. Vardhanabhuti, P. Fogarty, A. Rosell, S. Baeza, K. Fong, S. Lam
Journal: Journal of Thoracic Oncology (2024)
MA03.03 The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study
Authors: X. Chen, C. Dai, M. Peng, D. Wang, X. Sui, L. Duan, X. Wang, X. Wang, W. Weng, S. Wang, H. Zhao, Z. Wang, J. Geng, C. Chen, Y. Yan, Q. Hu, C. Jiang, H. Zheng, Y. Bao, C. Sun, Z. Cui, X. Zeng, H. Han, C. Xia, J. Liu, B. Yang, J. Qi, F. Ji, S. Wang, N. Hong, J. Wang, Y. Zhu, F. Yu, F. Yang
Journal: Journal of Thoracic Oncology (2024)
MA04.12 Uncovering Disparities and Trends in Lung Cancer Screening Based on Patient Race and Insurance Status
Authors: E.J. Zolfaghari, R. Tseng, P. Sather, T. Ermer, V. Mase, F. Detterbeck, L. Tanoue, G.A. Woodard
Journal: Journal of Thoracic Oncology (2024)
Epigenetic clocks and programmatic aging
Authors: David Gems, Roop Singh Virk, João Pedro de Magalhães
Journal: Ageing Research Reviews (2024)

The last decade has seen remarkable progress in the characterization of methylation clocks that can serve as indicators of biological age in humans and many other mammalian species. While the biological processes of aging that underlie these clocks have remained unclear, several clues have pointed to a link to developmental mechanisms. These include the presence in the vicinity of clock CpG sites of genes that specify development, including those of the Hox (homeobox) and polycomb classes. Here we discuss how recent advances in programmatic theories of aging provide a framework within which methylation clocks can be understood as part of a developmental process of aging. This includes how such clocks evolve, how developmental mechanisms cause aging, and how they give rise to late-life disease. The combination of ideas from evolutionary biology, biogerontology and developmental biology open a path to a new discipline, that of developmental gerontology (devo-gero). Drawing on the properties of methylation clocks, we offer several new hypotheses that exemplify devo-gero thinking. We suggest that polycomb controls a trade-off between earlier developmental fidelity and later developmental plasticity. We also propose the existence of an evolutionarily-conserved developmental sequence spanning ontogenesis, adult development and aging, that both constrains and determines the evolution of aging.
Regulation of histidine metabolism by Lactobacillus Reuteri mediates the pathogenesis and treatment of ischemic stroke
Authors: Kangrui Hu, Zhihao Zhou, Haofeng Li, Jijun Xiao, Yun Shen, Ke Ding, Tingting Zhang, Guangji Wang, Haiping Hao, Yan Liang
Journal: Acta Pharmaceutica Sinica B (2024)

Increasing evidence has underscored the significance of post-stroke alterations along gut-brain axis, while its role in pathogenesis and treatment of ischemic stroke (IS) remains largely unexplored. This study aimed to elucidate the therapeutic effects and action targets of Panax notoginseng saponins (PNS) on IS and explore a novel pathogenesis and treatment strategy of IS via profiling the microbial community and metabolic characteristics along gut-brain axis. Our findings revealed for the first time that the therapeutic effect of PNS on IS was microbiota-dependent. Ischemia/reperfusion (I/R) modeling significantly down-regulated Lactobacilli in rats, and PNS markedly recovered Lactobacilli, particularly Lactobacillus reuteri (L.Reu). Metabolomics showed a significant reduction in serum histidine (HIS) in clinical obsolete IS patients and rehabilitation period I/R rats. Meanwhile, the L.Reu colonization in I/R rats exhibited significant neuroprotective activity and greatly increased HIS in serum, gut microbiota, and brain. Moreover, exogenous HIS demonstrated indirect neuroprotective effects through metabolizing to histamine. Notably, vagus nerve severance in I/R rats was performed to investigate HIS's neuroprotective mechanism. The results innovatively revealed that PNS could promote HIS synthesis in gut by enhancing L.Reu proportion, thereby increasing intracerebral HIS through peripheral pathway. Consequently, our data provided novel insights into HIS metabolism mediated by L.Reu in the pathogenesis and treatment of IS.
Global practice variation of suppressive antimicrobial treatment for prosthetic joint infections: A cross-sectional survey study
Authors: Jaap L J Hanssen, Maaike G J Gademan, Marjan Wouthuyzen-Bakker, Joshua S Davis, David Dewar, Laurens Manning, David Campbell, Joffrey van Prehn, Andy O Miller, Robert J P van der Wal, Henrica M J van der Linden, Nicolás W Cortés-Penfield, Alex Soriano, Mark G J de Boer, Henk Scheper
Journal: Journal of Infection (2024)

To identify global differences in the use of suppressive antimicrobial therapy (SAT) in the management of prosthetic joint infection (PJI).
Exosomes from Hypoxic Urine-derived Stem Cells Facilitate Healing of Diabetic Wound by Targeting SERPINE1 through miR-486-5p
Authors: Ming-Hui Fan, Xiu-Zhen Zhang, Yan-Lin Jiang, Jin-Kui Pi, Ji-Ye Zhang, Yue-Qi Zhang, Fei Xing, Hui-Qi Xie
Journal: Biomaterials (2024)
Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series
Authors: Fernanda Eduarda das Neves Martins, Jannifer Oliveira Chiang, Bruno Tardelli Diniz Nunes, Bethania de Freitas Rodrigues Ribeiro, Lívia Carício Martins, Lívia Medeiros Neves Casseb, Daniele Freitas Henriques, Consuelo Silva de Oliveira, Ethel Leonor Noia Maciel, Rafael da Silva Azevedo, Layna de Cássia Campos Cravo, André Rodrigues Façanha Barreto, André Luiz Santos Pessoa, Arnaldo Jorge Martins Filho, Jorge Rodrigues de Sousa, Lavinia Schuler-Faccini, Juarez Antônio Simões Quaresma, Pedro Fernando da Costa Vasconcelos, Raimunda do Socorro da Silva Azevedo
Journal: The Lancet Infectious Diseases (2024)
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study
Authors: Gabriel C Scachetti, Julia Forato, Ingra M Claro, Xinyi Hua, Bárbara B Salgado, Aline Vieira, Camila L Simeoni, Aguyda R C Barbosa, Italo L Rosa, Gabriela F de Souza, Luana C N Fernandes, Ana Carla H de Sena, Stephanne C Oliveira, Carolina M L Singh, Shirlene T S de Lima, Ronaldo de Jesus, Mariana A Costa, Rodrigo B Kato, Josilene F Rocha, Leandro C Santos, Janete T Rodrigues, Marielton P Cunha, Ester C Sabino, Nuno R Faria, Scott C Weaver, Camila M Romano, Pritesh Lalwani, José Luiz Proenca-Modena, William M de Souza
Journal: The Lancet Infectious Diseases (2024)

Oropouche virus is an arthropod-borne virus that has caused outbreaks of Oropouche fever in central and South America since the 1950s. This study investigates virological factors contributing to the re-emergence of Oropouche fever in Brazil between 2023 and 2024.
The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives
Authors: Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, Paolo Curatolo
Journal: The Lancet Child & Adolescent Health (2024)